Assembly Bio Q2 net loss narrows to $3.9M; cash $320.4M, pipeline advances

ASSEMBLY BIOSCIENCES, INC.

2026-Q2 EPS reported -$0.72 revenue$21,587,000

Q2 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) year ago; Gilead revenue $13.4M vs $9.6M.
Cash, equivalents, marketable securities $320.4M at June 30, 2026; $115M gross financing completed; runway into 2029.
ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 expected Q1 2027.
GS-1179 selected for Phase 2 in recurrent genital herpes by year-end 2026; opt-in decision on 40% U.S. cost-profit share pending Gilead cost estimates.
$75M Gilead extension payment due Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.